TCGA-BH-A0H9-01A-11R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 42
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.440
- OXIDATIVE_PHOSPHORYLATION+0.370
- MYC_TARGETS_V1+0.360
- FATTY_ACID_METABOLISM+0.330
- ADIPOGENESIS+0.310
- MTORC1_SIGNALING+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- ESTROGEN_RESPONSE_LATE+0.250
- MYC_TARGETS_V2+0.250
- DNA_REPAIR+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.430
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.350
- ANGIOGENESIS-0.330
- KRAS_SIGNALING_UP-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- HYPOXIA-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202419 | — | — | 0.883 |
| 2 | DRR168570 | — | — | 0.874 |
| 3 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.870 |
| 4 | SRR8942974 | — | — | 0.865 |
| 5 | SRR10900021 | — | — | 0.857 |
| 6 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.857 |
| 7 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.857 |
| 8 | AUR-AFE4-TTM6-A-1-1-R-A742-41 | — | C | 0.855 |
| 9 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.848 |
| 10 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |